Search Results for: "Other News to Note"
-
Other News To Note
The compound suppressed cancer progression in an animal model of melanomaBioWorld International | Wednesday, May 22, 2013 -
Other News To Note
The compound suppressed cancer progression in an animal model of melanomaBioWorld Today | Friday, May 17, 2013 -
Other News To Note
Ltd., said Harvard Medical School presented data at the Association for Research in Vision and Ophthalmology conference in Seattle showing a major link between vascular endothelial growth factor (VEGF)-C levels and age-related macular degeneration (AMD) and that assessment of Opthea's drug development candidate, VGX-300 (a soluble form of VEGF receptor-3 that blocks VEGF-C and VEGF-D) in animal models of wet AMD confirmed its potential as a new therapy for the diseaseBioWorld International | Wednesday, May 15, 2013 -
Other News To Note
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said its SynCon DNA vaccine against Ebola and Marburg filoviruses induced strong and broad immune responses and demonstrated 100 percent protection against death following a challenge with multiple variants of the pathogens in two animal modelsBioWorld Today | Wednesday, May 15, 2013 -
Other News To Note
Pluristem Therapeutics Inc., of Haifa, Israel, said its PLacental eXpanded (PLX) cells tested in preclinical animal models of preeclampsia effectively improved several parameters of the diseaseBioWorld Today | Tuesday, May 14, 2013 -
Other News To Note
Acceleron presented data on the effects of its investigational protein therapeutic, ACE-536, on correcting anemia and ineffective erythropoiesis in an animal modelBioWorld Today | Monday, May 13, 2013 -
Other News To Note
Medicago's technology requires only the genetic sequence of the viral strain to produce an influenza vaccine, and the H7 VLP is now being purified in preparation for immunogenicity studies in animal modelsBioWorld Today | Thursday, May 9, 2013 -
Other News To Note
Cel-Sci Corp., of Vienna, Va., reported findings from an efficacy study in a second animal model of rheumatoid arthritis (RA) using its LEAPS technologyBioWorld Today | Tuesday, May 7, 2013 -
Other News To Note
Atox Bio Ltd., of Ness Ziona, Israel, said data from an animal model of necrotizing soft-tissue infection, also known as flesh-eating bacteria, demonstrated that the administration of a single dose of AB103, given several hours after infection even without antibiotics, increased survival in animals and reduced tissue necrosis, inflammation and bacterial burden at the site of infection without compromising the immune responseBioWorld International | Wednesday, April 17, 2013 -
Other News To Note
Atox Bio Ltd., of Ness Ziona, Israel, said data from an animal model of necrotizing soft-tissue infection, also known as flesh-eating bacteria, demonstrated that the administration of a single dose of AB103, given several hours after infection even without antibiotics, increased survival in animals and reduced tissue necrosis, inflammation and bacterial burden at the site of infection without compromising the immune response...Critical Outcome Technologies Inc., of London, Ontario, completed aBioWorld Today | Wednesday, April 10, 2013 -
Other News To Note
Data also showed SG100 can be safely applied in a relevant animal modelBioWorld Today | Tuesday, April 9, 2013 -
Other News To Note
The studies were carried out in animal modelsBioWorld Today | Wednesday, March 20, 2013 -
Other News To Note
Clinigen Group plc, of Burton-on-Trent, UK, and Theravance Inc., of South San Francisco, entered an exclusive commercialization agreement in the European Union and certain other countries located in Europe for Vibativ (telavancin) in nosocomial pneumonia, including ventilator-associated pneumonia, known or suspected to be caused by methicillin-resistant Staphylococcus aureus, when other alternatives are not suitable...In other news, Elan said its Tysabri (natalizumab) restructuring transaction isBioWorld International | Wednesday, March 13, 2013 -
Other News To Note
Prana Biotechnology Ltd., of Melbourne, Australia, said PBT434 was found to reduce the aggregation and accumulation of alpha-synuclein, a key protein in Parkinson's disease, in multiple transgenic animal models of the diseaseBioWorld Today | Thursday, March 7, 2013 -
Other News To Note
iBio Inc., of Newark, Del., will proceed with development of its antibody candidate for influenza following demonstration of safety and therapeutic efficacy in animal models, including models of H5N1 influenzaBioWorld Today | Tuesday, March 5, 2013 -
Other News To Note
The collaboration will determine whether PRO 140 can prevent or significantly diminish a primary HIV infection in an animal modelBioWorld Today | Wednesday, February 27, 2013 -
Other News To Note
The agreement covers evaluation of the proteins by in vitro and animal models to characterize the mechanism of action for Trichuris suis ova (CNDO-201) leading to identification of potential drug candidatesBioWorld Today | Monday, February 25, 2013 -
Other News To Note
The poster highlighted data demonstrating the in vivo memory-enhancing properties in two animal models of cognitive impairment as well as data on the action of BNC375 on the receptorBioWorld International | Wednesday, February 6, 2013 -
Other News To Note
The poster highlighted data demonstrating the in vivo memory-enhancing properties in two animal models of cognitive impairment as well as data on the action of BNC375 on the receptorBioWorld Today | Tuesday, February 5, 2013 -
Other News To Note
The company previously reported that an animal model of oral influenza candidate FluCide showed superior efficacy to Tamiflu (oseltamivir, Roche AG) against an H3N2 influenza virus strain, similar to the current dominant strain of influenzaBioWorld Today | Wednesday, January 16, 2013
Category
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.